secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0000950170-22-002421
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics appoints James Hassard as Chief Commercial Officer
------------------------------------------------------------

- James Hassard appointed CCO effective Feb 28, 2022; base salary $425,000, target bonus 40%.
- Will receive option to purchase 160,000 shares (25% vest Feb 28, 2023; balance monthly over 3 years).
- Hassard brings 30+ years biotech commercial experience; previously CCO at Arrowhead Pharma.
- Initial focus on paltusotine Phase 3 PATHFNDR program for acromegaly registration.
- Also overseeing commercial readiness for pipeline candidates CRN04777 and CRN04894.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/0000950170-22-002421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/crnx-20220228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer